Additional file 2

Incremental quarterly relapse count over 1 year

Patients treated with placebo had numerically higher numbers of relapses than patients treated with IFN β-1a SC tiw over each 3-month incremental period during Year 1 of the PRISMS trial.




Fig. S1 Mean number of clinical relapses over each 3-month interval.

IFN β-1a: interferon beta-1a; SC: subcutaneous; tiw: three times weekly.